Qiuzhong Pan

Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial

Xing Zhang, Bu-Shu Xu, Qiuzhong Pan, Ruiqing Peng et autres

PURPOSE: Advanced sarcomas lack effective maintenance therapies after first-line chemotherapy. We present long-term phase 1 results evaluating multi-antigen stimulated cell therapy-I (MASCT-I), a novel immunotherapy integrating dendritic cell vaccination with adoptive T-cell transfer, as maintenance treatment (NCT03034304). PATIENTS AND METHODS: Thirty-one patients …

cn (code pays fourni par la source)

Annexin A3 potentiates lenvatinib resistance in hepatocellular carcinoma through multiple approaches amplified by a positive feedback loop

Yingqin Zhu, Yue Huang, Mengjia Song, Jieying Yang et autres

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies with limited treatment options. Lenvatinib is a first-line drug for advanced HCC. However, its effect on patient survival is limited and patients ultimately develop disease progression due to drug resistance. In this …

cn (code pays fourni par la source)

The CXCL10‐CXCR3 Axis Induces Tumor‐Associated Neutrophils to Interfere with CTLs‐Mediated Antitumor Activity in EBV‐Associated Epithelial Cancers

Dijun Ouyang, Tong Xiang, Yuanyuan Chen, Mengjia Song et autres

Although Epstein-Barr virus (EBV)-associated epithelial cancers are categorized as immunologically "hot" tumors, they have unsatisfactory responses to immunotherapy. Increasing evidence has shown that therapeutic failure is due to an immunosuppressive tumor microenvironment established by EBV. In this study, a negative correlation is …

cn (code pays fourni par la source)

The efficacy and safety of gemcitabine and docetaxel in pseudomyogenic hemangioendothelioma: a multi-center experience

Qiyan Cai, Bu-Shu Xu, Peng Zhang, Jie Ma et autres

BACKGROUND: Pseudomyogenic hemangioendothelioma (PHE) is a rare, locally aggressive vascular tumor. Less than 200 cases of PHE have been reported. Surgery is the cornerstone of PHE treatment, and the data on systemic treatment is limited. METHODS: A retrospective multicenter study was conducted …

cn (code pays fourni par la source)

Multicenter phase II study of anlotinib and toripalimab in patients with advanced soft tissue sarcoma (STS) and bone sarcoma (BS).

Xing Zhang, Qiuzhong Pan, Peng Zhang, Lihong Zhang et autres

11556 Background: This multicenter phase II study aims to evaluate the efficacy and safety of anlotinib combined with toripalimab in the treatment of patients (pts) with advanced STS or BS. Methods: Pts with advanced STS or BS, 14-70 years, at least one …

cn (code pays fourni par la source)

A phase II, multicenter trial of the combination of chidamide and toripalimab in patients with advanced soft tissue sarcoma: Efficacy updates.

Xing Zhang, Ruiqing Peng, Peng Zhang, Wenhua Zhan et autres

11560 Background: Chidamide is an oral subtype-selective histone deacetylase (HDAC) inhibitor which is effective on the patients with hematological tumors and could be hoped to enhance the efficacy of checkpoint blockade therapies and regulate the host immune response. Here, we report the …

cn (code pays fourni par la source)

FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma

Wei Xiao, Liping Xu, Jinghua Wang, Kuai Yu et autres

Metastatic rhabdomyosarcoma is associated with poor survival and unsatisfactory treatment outcomes. Therefore, new immunotherapeutic methods are urgently required. Fibroblast growth factor receptor 4 (FGFR4), a new therapeutic target for rhabdomyosarcoma, plays a crucial role in its onset and development. This study aimed …

cn (code pays fourni par la source)

Supplementary Table 1 from SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib Sensitivity

Nan Fang, Bing Liu, Qiuzhong Pan, Tingting Gong et autres

Supplementary Table 1

Supplementary Figure 1 from SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib Sensitivity

Nan Fang, Bing Liu, Qiuzhong Pan, Tingting Gong et autres

Supplementary Figure 1. Chemical structure of NMDl14

Supplementary Table 1 from SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib Sensitivity

Nan Fang, Bing Liu, Qiuzhong Pan, Tingting Gong et autres

Supplementary Table 1

Data from SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib Sensitivity

Nan Fang, Bing Liu, Qiuzhong Pan, Tingting Gong et autres

Abstract Hepatocellular carcinoma (HCC) has a pathogenesis that remains elusive with restricted therapeutic strategies and efficacy. This study aimed to investigate the role of SMG5, a crucial component in nonsense-mediated mRNA decay (NMD) that degrades mRNA containing a premature termination codon, in …

Data from SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib Sensitivity

Nan Fang, Bing Liu, Qiuzhong Pan, Tingting Gong et autres

Abstract Hepatocellular carcinoma (HCC) has a pathogenesis that remains elusive with restricted therapeutic strategies and efficacy. This study aimed to investigate the role of SMG5, a crucial component in nonsense-mediated mRNA decay (NMD) that degrades mRNA containing a premature termination codon, in …